.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Cipla
Chinese Patent Office
UBS
Daiichi Sankyo
US Army
Fish and Richardson
Medtronic
Moodys

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,496,804

« Back to Dashboard

Claims for Patent: 5,496,804

Title: Method for treating taxol side-effects with G-CSF
Abstract:A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.
Inventor(s): Reed; Eddie (Germantown, MD), Kohn; Elise (Olney, MD), Sarosy; Gisele (Silver Spring, MD)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Application Number:08/342,797
Patent Claims: 1. A method of treating a host being treated with taxol in an amount sufficient to cause a side effect selected from the group consisting of myelosupression, mucositis, and peripheral neuropathy, which method comprises administering to said host granulocyte colony-stimulating factor in an amount effective to alleviate or prevent said side effect.

2. The method of claim 1, wherein said host is being treated with taxol in an amount exceeding about 175 mg/m.sup.2 / 21 days.

3. A method of claim 1, wherein said side effect is myelosuppression or mucositis.

4. The method of claim 3, wherein said granulocyte colony-stimulating factor is administered in an amount of at least about 5 .mu.g/kg/day.

5. The method of claim 4, wherein said granulocyte colony-stimulating factor is administered in an amount of about 10 to about 20 .mu.g/kg/day.

6. The method of claim 1, wherein said host is being treated with taxol once every three weeks and said granulocyte colony-stimulating factor is administered daily for at least seven days following the taxol treatment.

7. The method of claim 6 wherein said host is being treated with taxol in an amount of about 200 to about 250 mg/m.sup.2 / 21 days.

8. The method of claim 1, wherein said host is being treated with taxol to treat a cancerous tumor.

9. The method of claim 8, wherein said cancerous tumor is a breast, lung or ovarian tumor.

10. The method of claim 9, wherein said cancerous tumor is an ovarian tumor.

11. The method of claim 10, wherein said host is being treated with taxol in an amount exceeding about 175 mg/m.sup.2 / 21 days.

12. The method of claim 11, wherein said granulocyte colony-stimulating factor is administered in an amount of at least about 5 .mu.g/kg/day.

13. The method of claim 12, wherein said granulocyte colony-stimulating factor is administered in an amount of about 10 to about 20 .mu.g/kg/day.

14. The method of claim 13, wherein said host is being treated with taxol once every three weeks and said granulocyte colony-stimulating factor is administered daily for at least seven days following the taxol treatment.

15. The method of claim 14, wherein said host is being treated with taxol in an amount of about 200 to about 250 mg/m.sup.2 / 21 days.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
US Department of Justice
Harvard Business School
Teva
McKinsey
Queensland Health
Moodys
US Army
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot